Skip to main content

Outcome-specific differences between randomized trials and real-world studies of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative advanced breast cancer: a meta-epidemiological analysis

In brief

Real-world breast cancer cohorts reported 52% response versus 37% in trials

Across 86 studies, adjusted model estimates put objective response at 51.8% in real-world cohorts and 36.6% in randomized trial arms. Symptom-based side effects were reported less often outside trials, but dose reductions were more common and treatment discontinuation was similar; differences in outcome definitions and how events were captured limit direct comparisons.

Journal
BMC cancer (Q2)
Published
24 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Lingyao Sun, Xueping Yang, Dachuang Zhou, Mingye Zhao, Xiatong Ke, Liuqing Zhu, et al.
PMID
43040468
DOI
10.1186/s12885-026-17197-3

Why clinicians should know about it

  • Picked for Epidemiology (top studies of the week, 22 November 2026): Meta-epidemiology compares trial and real-world outcome ascertainment

Abstract

BACKGROUND: Real-world evidence is increasingly interpreted alongside randomized clinical trial evidence in oncology, but reported outcomes may differ because of variation in patient selection, treatment composition, follow-up, ascertainment, documentation, and reporting. We examined whether outcomes differed between randomized trials and real-world studies of CDK4/6 inhibitors. METHODS: We searched PubMed, Embase, Cochrane CENTRAL, and Web of Science through December 2025 for phase 2/3 randomized trials and real-world cohort, registry, or postmarketing studies of CDK4/6 inhibitors plus endocrine therapy for first- or second-line treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Arm proportions were pooled separately using logit-transformed random-effects models, and between-source differences were assessed using mixed-effects meta-regression. RESULTS: Eighty-six studies were included: 31 randomized trials (40 arms; 7464 patients) and 55 real-world studies (101 cohorts; 30 858 patients). Real-world cohorts included older patients and greater first-line and palbociclib use. After aggregate-level mixed-effects meta-regression adjustment, the model-based objective response rate was higher in real-world cohorts than in trial arms (51.8% vs. 36.6%; P = .031). Laboratory-based adverse events did not differ significantly, whereas symptom-based adverse events were consistently lower in real-world cohorts. Adverse event-related discontinuation was similar (10.6% vs. 8.6%; P = .523), whereas AE-related dose reduction was higher in real-world cohorts (50.8% vs. 33.4%; P = .016). CONCLUSIONS: Reported single-arm outcomes differed between randomized trials and real-world studies, with the largest differences observed for response and symptom-based adverse-event outcomes. These estimates should be interpreted according to endpoint definition, denominator construction, ascertainment, and reporting. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420261397529.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.